Photon-counting CT to improve tumor targeting and dose accuracy in personalized radiotherapy (ANTHEM)
Exploring Photon-Counting CT for Enhanced Target Delineation and Dose Accuracy in Personalized Radiotherapy - ANTHEM
This project will test whether photon-counting CT can help doctors better define tumor borders and calculate radiation doses for adults receiving high-precision radiotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istituto Clinico Humanitas Academic / other |
| Locations | 1 site (Rozzano, Milan) |
| Trial ID | NCT07098247 on ClinicalTrials.gov |
What this trial studies
This observational imaging protocol uses photon-counting CT (PCCT) during radiotherapy planning to obtain higher-resolution, spectrally enriched images for patients with challenging tumor locations or who require cardiac-directed radiation. Images and derived tissue-characterization data will be compared with conventional planning information to examine differences in target delineation and dose calculations. The study enrolls adults treated with photon or proton radiotherapy at the enrolling center and collects imaging and dosimetric metrics without changing the prescribed therapy. Results will inform whether PCCT-derived information could be incorporated into routine radiotherapy workflows for more precise planning.
Who should consider this trial
Good fit: Adults (≥18 years) with tumors in anatomically challenging regions (brain, head and neck, liver, pancreas, prostate) or patients with cardiac disease requiring photon or proton radiotherapy at the enrolling center are ideal candidates.
Not a fit: Children and patients treated outside the enrolling hospital, as well as those with tumors in straightforward locations where standard imaging is already sufficient, are unlikely to receive direct benefit from this protocol.
Why it matters
Potential benefit: If successful, using PCCT could lead to more accurate tumor targeting and reduced radiation exposure to nearby healthy tissues.
How similar studies have performed: Early technical and pilot clinical work has shown that PCCT improves image resolution and tissue contrast, but strong evidence that it improves radiotherapy outcomes is still limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * ≥18 years old patients * tumors located in challenging anatomical regions (brain, head and neck, liver, pancreas prostate), or Cardiac disease requiring RT by photon or proton at our Institution. Exclusion criteria: \- 18 years old patients
Where this trial is running
Rozzano, Milan
- IRCCS Humanitas Research Hospital — Rozzano, Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Marta Scorsettti, MD, radiation oncologist — Humanitas University
- Study coordinator: Research study coordinator
- Email: laura.bonavita@humanitas.it
- Phone: +39 0282247026
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.